Opinion|Videos|July 8, 2024
Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC
The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What are the standard-of-care regimens for first-line treatment of HER2+ metastatic breast cancer (mBC)?
Advertisement
Related to this article
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN guidelines for select patients with previously treated breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Flashback: GI Cancer Decisions and News From July 2026
2
TNFR2 Advances as a Novel Target for Restoring Antitumor Immunity Across Lymphoma and Solid Tumors
3
Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued
4
CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease
5